In conclusion, our data show that IGF-I protects MTC primary cultures from the effects of everolimus and stimulates CT secretion by an mTOR mediated pathway that, in turn, may represent a therapeutic target in the treatment of aggressive MTCs. This evidence concerns the gene IGF1 and medullary thyroid gland carcinoma.